Exact Sciences (EXAS) Stock Forecast, Price & News

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Exact Sciences in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EXAS shares.
View EXAS analyst ratings or view top-rated stocks.

13 Wall Street analysts have issued 12 month price targets for Exact Sciences' shares. Their EXAS share price forecasts range from $60.00 to $100.00. On average, they anticipate the company's stock price to reach $80.35 in the next year. This suggests that the stock has a possible downside of 8.5%.
View analysts price targets for EXAS or view top-rated stocks among Wall Street analysts.

Exact Sciences' stock was trading at $49.51 at the beginning of 2023. Since then, EXAS shares have increased by 77.4% and is now trading at $87.81.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our EXAS earnings forecast.

Exact Sciences Co. (NASDAQ:EXAS) posted its quarterly earnings results on Tuesday, May, 9th. The medical research company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.37. The medical research company had revenue of $602 million for the quarter, compared to analyst estimates of $543.18 million. Exact Sciences had a negative trailing twelve-month return on equity of 16.64% and a negative net margin of 23.49%. Exact Sciences's quarterly revenue was up 23.7% on a year-over-year basis. During the same period in the prior year, the business earned ($1.04) EPS.

ETFs with the largest weight of Exact Sciences (NASDAQ:EXAS) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), ARK Innovation ETF (ARKK), First Trust Nasdaq Lux Digital Health Solutions ETF (EKG), Pinnacle Focused Opportunities ETF (FCUS), First Trust NYSE Arca Biotechnology Index Fund (FBT), First Trust Indxx Medical Devices ETF (MDEV), Principal Healthcare Innovators ETF (BTEC) and VanEck Biotech ETF (BBH).

Exact Sciences issued an update on its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $2.38 billion-$2.42 billion, compared to the consensus revenue estimate of $2.30 billion.

328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL), Block (SQ), Advanced Micro Devices (AMD), Walt Disney (DIS) and AbbVie (ABBV).

Exact Sciences trades on the NASDAQ under the ticker symbol "EXAS."

Exact Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (6.38%), Baillie Gifford & Co. (2.66%), Sumitomo Mitsui Trust Holdings Inc. (2.12%), Nikko Asset Management Americas Inc. (1.83%), Ensign Peak Advisors Inc (1.58%) and Artisan Partners Limited Partnership (1.51%). Insiders that own company stock include Canada Pension Plan Investment, D Scott Coward, Everett Cunningham, Graham Peter Lidgard, Jacob A Orville, Jacob A Orville, James Edward Doyle, James Herriott, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Kevin T Conroy, Sarah Condella and Torsten Hoof.
View institutional ownership trends.

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EXAS stock can currently be purchased for approximately $87.81.

Exact Sciences (NASDAQ:EXAS) has a market capitalization of $15.85 billion and generates $2.08 billion in revenue each year. The medical research company earns $-623,510,000.00 in net income (profit) each year or ($2.92) on an earnings per share basis.

The company employs 6,400 workers across the globe.

Exact Sciences' mailing address is 5505 ENDEAVOR LANE, MADISON WI, 53719. The official website for the company is www.exactsciences.com. The medical research company can be reached via phone at (608) 284-5700, via email at meganjones@exactsciences.com, or via fax at 608-284-5701.